Ladenburg raised the firm’s price target on Corcept Therapeutics (CORT) to $73.50 from $72 and keeps a Buy rating on the shares after the company reported “strong” Q3 revenue and raised 2024 revenue guidance. The firm cites the underlying Korylm business and increased revenue projections for 2024 and 2025 for its increased price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats
- Corcept Therapeutics reports Q3 EPS 41c, consensus 28c
- Corcept Therapeutics raises FY24 revenue view to $675M-$700M, consensus $661.1M
- Corcept Therapeutics Reports Strong Revenue and Future Plans